Peter Eickelmann

1.3k citations
19 papers · 1.1k · 1 hit paper · h-index 13

Impact in

Papers in

    • Genomics, phytochemicals, and oxidative stress 6
    • Glutathione Transferases and Polymorphisms 4
    • Receptor Mechanisms and Signaling 3
    • Chemical Synthesis and Analysis 3
    • Pancreatic function and diabetes 4

Peter Eickelmann

19 papers receiving 1.1k citations

Peter Eickelmann's Hit Papers

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors 2011 · 510 citations
5100+5+10Years since publication100200300400500

Peers

Peter Eickelmann
Comparison fields: 5 of 81
  • Endocrinology, Diabetes and Metabolism 512
  • Toxicology 48
  • Molecular Biology 557
  • Surgery 291
  • Nephrology 31
Replace Fuyong Du with:
Fuyong Du United States
Joseph R. Taylor United States
H Oftebro Norway
Korekiyo Wakitani Japan
Shlomit Koren Israel
Adriana Zuccollo Argentina
William R. Bensch United States
Sami Vaïsänen Finland
Eiji Kurosaki Japan
Dale E. Sharp United States
Peter Eickelmann relative to Fuyong Du United States Fuyong Du's profile →
Citations per field
00.5×1.5×2.3×
Fuyong Du · 1×
Citations per year

Countries citing papers authored by Peter Eickelmann

Since Specialization
Citations

This map shows the geographic impact of Peter Eickelmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Eickelmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Eickelmann more than expected).

Fields of papers citing papers by Peter Eickelmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Eickelmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Eickelmann. The network helps show where Peter Eickelmann may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Eickelmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Eickelmann Line = papers co-authored together Peter Eickelmann links everyone, so they are left out of the graph.

All Works

19 of 19 papers shown
#Work
1
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
Hit paper breakdown →
2011510
2 1997139
3 201167
4 199448
5 201143
6 200340
7 200332
8 201231
9 199130
10
Lowered amounts of the tissue-specific transcription factor LFB1 (HNF1) correlate with decreased levels of glutathione S-transferase alpha messenger RNA in human renal cell carcinoma.
199430
11 199429
12 201324
13 200220
14 200712
15 199612
16 19958
17 19968
18 19952
19 19951

About Peter Eickelmann

Peter Eickelmann is a scholar working on Molecular Biology, Surgery, Cellular and Molecular Neuroscience, Endocrinology, Diabetes and Metabolism and Organic Chemistry, having authored 19 papers that have together received 1.1k indexed citations. Recurring topics across this work include Genomics, phytochemicals, and oxidative stress (6 papers), Pancreatic function and diabetes (4 papers), Glutathione Transferases and Polymorphisms (4 papers), Diabetes Treatment and Management (3 papers), Receptor Mechanisms and Signaling (3 papers), Chemical Synthesis and Analysis (3 papers), Neuropeptides and Animal Physiology (3 papers) and Adenosine and Purinergic Signaling (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (512 citations), Toxicology (48 citations), Molecular Biology (557 citations), Surgery (291 citations) and Nephrology (31 citations). Peter Eickelmann has collaborated with scholars based in Germany, United States and Italy. Frequent co-authors include Michael Mark, Rolf Grempler, Matthias Eckhardt, Leo Thomas, Thomas Klein, Achim Sauer, Frank Himmelsbach, Remko A. Bakker, Dale E. Sharp and Wolfgang A. Schulz. Their work appears in journals such as FEBS Letters, Diabetes Obesity and Metabolism, European Journal of Biochemistry, Diabetologia and Carcinogenesis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact